DBVT

DBV Technologies

8.91 USD
+0.93
11.65%
At close Apr 21, 4:00 PM EDT
1 day
11.65%
5 days
19.28%
1 month
78.56%
3 months
97.12%
6 months
153.85%
Year to date
174.15%
1 year
34.80%
5 years
-81.00%
10 years
-96.53%
 

About: DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Employees: 109

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

14.01% less ownership

Funds ownership: 16.67% [Q3] → 2.66% (-14.01%) [Q4]

25% less capital invested

Capital invested by funds: $11.3M [Q3] → $8.46M (-$2.8M) [Q4]

25% less funds holding

Funds holding: 24 [Q3] → 18 (-6) [Q4]

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

92% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 12

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$10
12%
upside
Avg. target
$10
12%
upside
High target
$10
12%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Citizens Capital Markets
Jonathan Wolleben
34% 1-year accuracy
23 / 67 met price target
12%upside
$10
Market Outperform
Reiterated
4 Mar 2025

Financial journalist opinion

Based on 5 articles about DBVT published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced: The audited financial statements for the year ended December 31, 2024 were approved by the Board of Directors on April 11, 2025, and present no changes from the unaudited financial statements examined by the Board of Directors on March 23 and published in the Company's press release dated March 24, 2025; The filing, for the year ended December 31, 2024, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). In compliance with French law, the 2024 URD includes the following information: The Annual Financial Report; The Management Report (“rapport de gestion”); The Corporate Governance Report; The description of the Share Buyback Program.
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
Negative
MarketBeat
1 week ago
3 Biopharmaceutical Stocks Bucking the Sell-Off
With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be looking for an opportunity. While it's true that some of the biggest firms in the world started April with major share price discounts, investors may want to find companies to target that have been more or less bulletproof in the extreme uncertainty characterizing the market.
3 Biopharmaceutical Stocks Bucking the Sell-Off
Positive
Market Watch
3 weeks ago
DBV Technologies ADRs Rise After Up to $306.9M in New Financing
American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million.
DBV Technologies ADRs Rise After Up to $306.9M in New Financing
Neutral
GlobeNewsWire
3 weeks ago
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
Châtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved DBV secures $125.5 million (€116.3 million) up front and up to $181.4 million (€168.2 million), subject to the full exercise of warrants DBV sufficiently funded through the expected Biologics License Application (BLA) submission to Food and Drug Administration (FDA) for the Viaskin® peanut patch in children 4 – 7-years-old and commercial launch, if approved DBV will host an investor conference call on Monday, March 31 st at 5:00pm ET (23h00 CET) to discuss the financing and FDA update DBV Technologies (the “Company” or “DBV”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT), a clinical-stage biopharmaceutical company dedicated to treating pediatric allergies, today announced a financing of up to $306.9 million (€284.5 million), including gross proceeds of $125.5 million (€116.3 million) to be received upon closing and an aggregate of up to ($181.4 million) (€168.2 million) in gross proceeds if all the warrants are exercised, subject to satisfaction of specified conditions. The VITESSE Phase 3 study hitting its primary endpoint will trigger an acceleration of the exercise period of some of the warrants.
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
Neutral
GlobeNewsWire
4 weeks ago
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results
Châtillon, France, March 24, 2025 DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin® Peanut Patch in 4 – 7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, and Reports 2024 Unaudited Financial Results 1 COMFORT Children supplemental safety study in children 4 – 7-years-old no longer required FDA confirms safety exposure data generated from VITESSE Phase 3 clinical study and VITESSE Open-Label Extension (OLE) are sufficient to support a Biologics License Application (BLA) for Viaskin peanut patch in children 4 – 7-years-old VITESSE topline results on-track for the fourth quarter of 2025 BLA submission for Viaskin peanut patch in children 4 – 7-years-old is now expected in the first half of 2026; DBV anticipates this path may accelerate potential launch, if approved by the FDA, by approximately one year DBV also reports unaudited financial results 1 for the full year 2024, including cash and cash equivalents DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT, the “Company”), a clinical-stage biopharmaceutical company, today announced that in a Written Responses Only to the Company's Type D IND meeting request, the U.S. Food and Drug Administration (FDA) agreed with the Company's proposal that the safety exposure data from the VITESSE Phase 3 study for Viaskin peanut patch in 4 – 7-year-olds will be sufficient to support a Biologics License Application (BLA) filing in this age group. As a result, the COMFORT Children supplemental safety study will no longer be required, which accelerates the timeline for a BLA submission of Viaskin® peanut patch in 4 – 7-year-olds with a peanut allergy.
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results
Neutral
GlobeNewsWire
1 month ago
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
Châtillon, France, February 25, 2025 DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the American Academy of Allergy, Asthma, and Immunology and World Allergy Organization (AAAAI/WAO) Joint Congress, February 28-March 3, 2025, in San Diego, CA. An oral abstract presentation by Dr. David Fleischer, FAAAAI, FACAAI, Professor of Pediatrics at Children's Hospital Colorado, will describe Month 60 (M60), end-of-study efficacy and safety results from PEOPLE (the open-label extension of the 12-month, double-blind placebo-controlled, Phase 3 PEPITES study in peanut allergic children aged 4-11 years).
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
Neutral
GlobeNewsWire
3 months ago
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated Information Châtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2024: 266,868 DBV Technologies shares, € 106,930.51.
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Positive
Benzinga
4 months ago
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids
On Wednesday, DBV Technologies SA DBVT reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years.
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids
Neutral
GlobeNewsWire
4 months ago
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025 Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteria for post-marketing confirmatory study in toddlers 1 – 3 years-old Company to host investor webcast today at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the successful outcome of recent written and oral communication with the U.S. Food and Drug Administration (FDA) that provides a clear and well-defined regulatory pathway for the Viaskin Peanut patch program in toddlers 1 – 3-years-old. The FDA has formalized guidance on an Accelerated Approval for the Viaskin Peanut patch in toddlers 1 – 3-years-old.
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
Neutral
GlobeNewsWire
5 months ago
DBV Technologies Announces Plan to Implement ADS Ratio Change
Châtillon, France, November 11, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J200), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one (1) ordinary share to a new ADS Ratio of one (1) ADS to five (5) ordinary shares (the “ADS Ratio Change”). The Company anticipates that the ADS Ratio Change will be effective on or about November 29, 2024 (the “Effective Date”).
DBV Technologies Announces Plan to Implement ADS Ratio Change
Charts implemented using Lightweight Charts™